Drug
SB 649868
SB 649868: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| SB-649868 NCT00426816 | Phase 2 | Sleep Initiation and Maintenance Disorders |
Latest
No recent events.
Follow SB 649868 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.